Trump’s FDA Nominee Faces Peptide Regulation Battle Ahead of Senate Confirmation
President Donald Trump’s nominee to lead the Food and Drug Administration, Dr. Heidi Overton, is stepping into one of the most contentious health policy fights of the year: whether unapproved peptides should be more widely available through compounding pharmacies. The Pro‑Peptide Push In July, Health and ...